Key Developments For SeraCare Life Sciences, Inc.
SeraCare Life Sciences, Inc. (SRLS.O) (Consolidated Issue listed on NASDAQ Capital Market)
SeraCare Life Sciences, Inc. Shares Rise On Higher Than Expected Fourth Quarter Profit-Reuters
Reuters reported that shares of SeraCare Life Sciences, Inc. rose as much as 24%, a day after it reported higher-than-expected quarterly earnings on lower costs.
SeraCare Life Sciences, Inc. Awarded Multiple Contracts From CDC and NIH To Support HIV Research and Accuracy Of HIV Testing
SeraCare Life Sciences, Inc. announced that the Company has been awarded two new contracts from the Centers for Disease Control (CDC) and the National Institutes of Health (NIH) and that a third existing contract has been expanded by the NIH to support federally-funded HIV research and testing. These contracts represent a combined $10.8 million in new funding if all options are exercised over the life of the contracts. Under a new contract awarded by the Centers for Disease Control (CDC) as part of the CDC's HIV-1 Rapid Test Proficiency Program, SeraCare will support efforts to ensure that laboratories performing HIV-1 assays are achieving accurate results. The Company will provide well characterized HIV-1 positive and negative plasma and will test, dispense and distribute panels to approximately 650 laboratories participating in this performance evaluation program, which is used as a self-assessment tool for facilities performing HIV-1 rapid testing. The five-year contract is valued at over $3.6 million if all options are exercised by the CDC. Under a second new contract awarded by PPD, Inc. to support the NIH's Division for HIV Clinical Research Support Services, SeraCare will collect, characterize, assemble and distribute a comprehensive panel of current worldwide HIV strains.
SeraCare Life Sciences, Inc. Launches First-to-Market HPV Genotype Performance Panel
SeraCare Life Sciences, Inc. announced that the Company has launched a new product in its diagnostic controls and panels portfolio-the SeraCare Human Papillomavirus (HPV) Genotype Performance Panel.
SeraCare Life Sciences, Inc. Brings Browsing and Ordering of Products and Services Online
SeraCare Life Sciences, Inc. announced the launch of its new website and electronic catalog. This website complements SeraCare's global marketing initiative, bringing browsing and ordering of SeraCare products and services to the desktop and fingertips of life-science professionals involved in clinical testing or drug, vaccine and diagnostic research, development and manufacturing.
SeraCare Life Sciences, Inc. Announces Completion of SEC Investigation
SeraCare Life Sciences, Inc. announced that it has been notified by the Securities and Exchange Commission (SEC) that the SEC has completed its investigation of the Company and does not intend to recommend any enforcement action against the Company. The investigation was initiated in 2005 while the Company was under prior management and focused on the Company's financial statements filed with the SEC prior to September 30, 2005, the accounting documentation related to these financial statements and the ability of the Company's auditors to rely on representations of the Company's former management.
